Managing MCL After BTKi Failure: The Expanding Role of CAR T-Cell Therapy

Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Michael Wang, MD

For patients with mantle cell lymphoma (MCL) who relapse after BTK inhibitor (BTKi) therapy, treatment decisions can be complex and time sensitive. That’s why understanding how tumor biology and risk features can guide selection between immunomodulatory regimens and CAR T-cell therapy is essential. Tune in to hear Dr. Charles Turck speak with Dr. Michael Wang about practical, evidence-based strategies for managing relapsed/refractory MCL. Dr. Wang is a Professor in the Department of Lymphoma and Myeloma in the Department of Stem Cell Transplantation at MD Anderson Cancer Center in Houston, Texas.

Видео Managing MCL After BTKi Failure: The Expanding Role of CAR T-Cell Therapy канала ReachMD